• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

cafead

Administrator
Staff member
  • cafead   Feb 28, 2023 at 11:02: AM
via Acumen Pharmaceuticals plans to conduct a Phase II or Phase II/III clinical trial investigating the monoclonal antibody ACU193 in patients with early Alzheimer’s disease (AD), says president and CEO Daniel O’Connell. The company expects to initiate the next phase trial in 2024.

article source
 

<